Truist Securities Maintains Buy on CVS Health, Raises Price Target to $108

Benzinga Newsdesk www.benzinga.com Positive 77.6%

Neg 0% Neu 0% Pos 77.6%

Truist Securities analyst David Macdonald maintains CVS Health (NYSE:CVS) with a Buy and raises the price target from $102 to $108.